Menu

Pharmaceuticals

Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection

, , ,

12-Week Course of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) in Japanese Phase 3 Study Ledipasvir/Sofosbuvir Simplifies Hepatitis C Treatment to a Single, Once-Daily Tablet FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 24, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has submitted a New Drug Application (NDA) to Japan’s Pharmaceutical and Medical Devices Agency […]

Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer

, , ,

Data to be Presented at European Society for Medical Oncology Congress in Madrid FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 17, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, […]

First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study

, , ,

AMBITION Study of Ambrisentan/Tadalafil Combination Therapy Versus Monotherapy Achieves Primary Endpoint of Time to First Clinical Failure Event Data Presented at the ERS International Congress 2014 MUNICH–(BUSINESS WIRE)–Sep. 8, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in […]

Roche’s RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA)

, ,

Treating RA patients with severe, progressive disease in the first two years after diagnosis (early RA) could prevent damage to joints and stop the disease from progressing1,2 RoACTEMRA with and without MTX achieved greater inhibition of structural joint damage compared with MTX alone in the early RA population1 Basel, 8 September 2014 – Roche (SIX: […]

Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity

, , , ,

The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays Basel, 2 September 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening in markets accepting the CE mark. The […]

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

, , ,

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 25, 2014– Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Zydelig® (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients […]

Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries

, , ,

Agreement provides license for generic production of tenofovir alafenamide, an investigational agent for the treatment of HIV and chronic hepatitis B MELBOURNE, Australia–(BUSINESS WIRE)–Jul. 24, 2014– Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s […]

U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

, , ,

82 Percent Reduction in Risk of Disease Progression or Death When Combined with Rituximab Compared to Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 23, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Zydelig® (idelalisib) 150 mg tablets for the […]

Bayer Early Excellence in Science Award: EUR 30,000 for international research scientists

, , ,

Dr. Abigail Doyle (Associate Professor at Princeton University, USA) wins the „Chemistry“ category / Dr. Steven Spoel (Principal Investigator at the University of Edinburgh, UK) takes the „Biology“ award /Dr. Javier Fernandez (Associate Researcher at Wyss Institute/Harvard University, Boston, USA) awarded prize in the „Materials“ field Leverkusen, January 10, 2013 – The winners of the Bayer […]

Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies

, , , ,

Cambridge, Mass and Richmond, Calif. –  January 9, 2014 – Biogen Idec (NASDAQ:BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The agreement will enable Biogen Idec to further enhance its […]

«‹ 11 12 13 14›»